Bayer Appoints New General Managers for Nutritionals and Digestive Health Businesses

WHIPPANY, N.J.–()–Bayer Consumer Health has appointed new General Managers to lead its Nutritionals and Digestive Health businesses, two of its fastest growing categories.

After 16 years at Bayer, Lisa Perez is being named General Manager and Vice President Marketing – Nutritionals. In addition, David Ball has been appointed General Manager and Vice President Marketing – Digestive Health. Perez and Ball will start these new roles on November 1.

Perez currently serves as Senior Director Marketing, Pain/Cardio and has been instrumental in delivering some of the boldest marketing campaigns for Consumer Health, such as the Bayer Aspirin “Your Heart Isn’t Just Your Own” and Bayer Pain “Modern Pains” which resulted in unprecedented growth and share gains. She has also been involved in the successful relaunch of Midol®, which resulted in award-winning design, branding and a bold purpose campaign called “Stop Apologizing. Period.” Midol® is currently the No. 1 growing brand in the division with year over year double-digit growth. Most recently, she supported the AleveX™ launch, which is expected to further accelerate the Aleve® turnaround.

In 2005, Perez began her career at Bayer as an Assistant Customer Marketing Manager, and since then has advanced into leadership positions in Marketing, working on brands such as One A Day®, Alka-Seltzer Plus®, and Coppertone®.

Perez graduated from Kutztown University and received her MBA from Fairleigh Dickenson University.

Ball currently serves as Care/of Retail Go-to-Market Lead responsible for driving the launch of Care/of into retail, developing the go-to market strategies for the retail class of trade, as well as broader Marketing and Strategy for the company. He successfully launched Care/of into Target, resulting in three product offerings ranking in the top 20 new products for 2021. In true start-up mentality, he owned all facets of the retail proposition including product supply, marketing, sales, media, insights and innovation pipeline development.

Most recently, Ball served as the Director on the Accelerator team where he led multiple strategies for the division in coordination with Bayer’s Board of Management and Consumer Health Executive Committee, including the Care/of acquisition and the LIFT initiative for North America which is dedicated to increasing healthcare access to the underserved. Before joining Bayer in 2019, he worked at P&G as the commercial leader on multiple iconic OTC brands such as Vicks, Align and Metamucil.

Ball holds a PhD in Genetics and Molecular Biology from the University of Sheffield and worked as an academic and a scientist at the University of California – Berkeley before his time in CPG.

Perez and Ball will report directly to Dave Tomasi, Chief Commercial Officer for Consumer Health North America.

Lisa and David are both exceptional leaders who have delivered significant growth for our business,” Tomasi said. “Lisa is an inspiring and empowering leader who has led her team through toughest of times, while David brings a strong set of skills and experiences to his new role, including business leadership, science, and marketing. I look forward to partnering with them both to drive further growth for our Nutritionals and Digestive Health categories.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.us.

Social Media Channels

– Facebook: BayerUnitedStates
– Twitter: BayerUS
– Instagram: BayerUS
– YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Source

Recent Articles

Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.